Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Head & Neck 3Gynecologic 3Gastrointestinal 3Tumor-Agnostic 2Other hematologic neoplasm 2CNS 2Breast 2Sarcoma 1Other solid neoplasm 1Myeloid 1Genitourinary 1Classical hematology 1

Conditions

Fanconi Anemia 1

Interventions

Cyclophosphamide 93fludarabine phosphate 86Busulfan 63Cyclosporine 57Peripheral Blood Stem Cell Transplantation 54Mycophenolic Acid 54Whole-Body Irradiation 53Epoetin Alfa 53Antilymphocyte Serum 43fludarabine 42Filgrastim 41Cytarabine 41Tacrolimus 39Melphalan 38Darbepoetin alfa 38Methotrexate 34Radiotherapy 32Cord Blood Stem Cell Transplantation 28Granulocyte Colony-Stimulating Factor 23Methylprednisolone 21Etoposide 21apixaban 18eltrombopag 16Thiotepa 16Dalteparin 16ferric carboxymaltose 14Daunorubicin 14Azacitidine 14Alemtuzumab 14thymoglobulin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × prexasertib × Classical hematology × Clear all
NCT02873975 2022-10-21

A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

Dana-Farber Cancer Institute

Phase 2 Completed
27 enrolled 13 charts
Classical hematology

Fanconi Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡